KAO JOHN E sold $6.1M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $20.36 ($19.65–$20.60, $6.07M total) across 2 trades on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jun 12, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$6.07M is newly reported; the 10b5-1 designation reduces interpretive value regarding near-term fundamentals.

02

Market read

Provides a fresh, company-specific insider selling datapoint that can influence short-term sentiment but lacks fundamental catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance/clinical/regulatory updates, the signal is typically weak.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed June 12 (covering June 10 sales)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

CEO KAO JOHN E sold $6.07M of Alignment Healthcare shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is new and company-specific, but the transaction is explicitly under a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

No direct sector read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • KAO JOHN E

    Chief Executive Officer and director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, indicating scheduled selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.